Akoya Biosciences Unveils Comprehensive Roadmap of Innovations at Inaugural Spatial Day Event
16 December 2021 - 4:00AM
Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology
Company®, today unveiled its next-generation of innovations to
enable unbiased spatial phenotyping at unprecedented speeds,
setting a new standard in spatial biology. The comprehensive
roadmap includes additions to the instrument portfolio and novel
chemistries that, collectively, make it the most integrated suite
of solutions spanning discovery, translational and clinical
research.
As part of the instrument portfolio expansion, the company
announced the imminent launch of the PhenoCycler-Fusion System, a
transformational platform that allows researchers to map a million
cells in as little as 10 minutes. The new system combines the
strengths of the company’s best-in-class ultrahigh multiplex
cycling technology, CODEX®, and the industry-leading high-speed
imaging capabilities of its Vectra® Polaris system, into an
integrated platform that is positioned to revolutionize spatial
discovery and translational research. This fusion of the company’s
foundational technological capabilities delivers ultrahigh
multiplexed imaging at single-cell and subcellular resolution
across entire slides, more than ten times faster than traditional
methods.
To underscore the powerful future of this integrated spatial
phenotyping portfolio, Akoya is rebranding its existing products.
Effective January 2022, CODEX will become PhenoCycler, the
Phenoptics™ workflow will be renamed as the PhenoImager™ workflow,
and the Vectra Polaris instrument will become the PhenoImager HT
instrument.
In addition to enabling unbiased spatial discovery through rapid
whole-slide imaging, the PhenoCycler-Fusion has a tunable workflow
that allows researchers to run large panels in discovery mode and
focused panels in high throughput mode. This unique capability
accelerates the translation of spatial biomarker signatures onto
the PhenoImager HT instrument for clinical research
applications.
With the PhenoCycler-Fusion at the core of its strategic
roadmap, Akoya also previewed upcoming innovations in its reagent
chemistry. For the first time, the company will enable spatial
transcriptomics capabilities on its platforms, leveraging a novel
RNA chemistry. Incorporating both proteomic and transcriptomic
analysis capabilities from the same tissue sample makes
PhenoCycler-Fusion the only practical solution for complete
multiomic assessment of cellular phenotypes, with whole-slide
spatial context.
In addition, Akoya also previewed a novel protein
chemistry that supports the development of universal barcoded
antibodies to run on both its PhenoCycler-Fusion and PhenoImager
instruments, enabling researchers to optimize the same spatial
phenotyping assay from discovery, all the way to clinical
research.
“Our comprehensive roadmap for unbiased, multiomic spatial
phenotyping will enable our customers to further accelerate their
use of our platforms, enabling more rapid discovery and validation
of predictive biomarkers,” said Brian McKelligon, Chief Executive
Officer of Akoya Biosciences. “We’re excited to see how the
scientific community will apply these innovations in advancing our
understanding of biology and human health.”
The PhenoCycler-Fusion System will be shipped in limited
quantities to selected sites in December 2021, with a full
commercial launch set for January 2022. More details on the
universal RNA and protein chemistries will be revealed throughout
2022. To stay up-to-date on the launch, sign up at
akoyabio.com/fusion.
A recording of Akoya’s Spatial Day Event can be accessed at
akoyabio.com/spatialday.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is
to bring context to the world of biology and human health through
the power of spatial phenotyping. The company offers comprehensive
single-cell imaging solutions that allow researchers to phenotype
cells with spatial context and visualize how they organize and
interact to influence disease progression and treatment response.
Akoya offers two distinct solutions, the CODEX® and Phenoptics™
platforms, to serve the diverse needs of researchers across
discovery, translational and clinical research. To learn more about
Akoya, visit akoyabio.com.
Investor Contact:Priyam ShahSr. Director,
Investor RelationsAkoya Biosciencesinvestors@akoyabio.com
Media Contact:
Michelle LinnBioscribe, Inc.774-696-3803
michelle@bioscribe.com
Photos accompanying this announcement are available
athttps://www.globenewswire.com/NewsRoom/AttachmentNg/b6bfa273-7790-4d66-b181-4cde08f11cdbhttps://www.globenewswire.com/NewsRoom/AttachmentNg/7bcb1249-2fc1-4805-82e7-c3027841d855
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Apr 2023 to Apr 2024